Mangalam Drugs And Organics Limited (MANGALAM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Mangalam Drugs And Organics Limited stock ₹29.66, price ₹28.60, upside +3.7%, quality 29 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Mangalam Drugs And Organics Limited
MANGALAM · NSEThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ₹23.78 – ₹189.50 · fair‑value band ₹22.14 – ₹44.27 · the ₹28.60 price screens below the ₹29.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.
Every Wednesday you see whether Mangalam Drugs And Organics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.
Show moreShow less
The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate.
It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base.
In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals.
Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications.
Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India.
Stock analysis
Mangalam Drugs And Organics Limited (MANGALAM) currently trades at ₹28.60, while our model-based Fair Value estimate is ₹29.66, so the stock looks roughly fairly valued today (gap 3.6%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: ₹22.14 (bear) to ₹44.27 (bull), the price of ₹28.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Mangalam Drugs And Organics Limited reported revenue of ₹2.3B in FY2026 versus ₹4.5B in FY2022, a compound −15.1%/yr. Reported net income was −₹444M in FY2026.
Key figures
Market cap ₹453M (≈ $4.8M) Micro · P/S ratio 0.20 · EPS (TTM) ₹−24.16 · Dividend yield 9.0% · Net margin −16.5% · Return on equity −35.2% · Return on assets (EBIT) 1.9% (5-year average) · Operating margin −5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 53% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 4%, MANGALAM screens cheaper than that median.
Fair Value models
All 1 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch MANGALAM, get fair value alerts →
Compare Mangalam Drugs And Organics Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs MANGALAM |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs MANGALAM |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs MANGALAM |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs MANGALAM |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs MANGALAM |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs MANGALAM |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs MANGALAM |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs MANGALAM |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs MANGALAM |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs MANGALAM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Mangalam Drugs And Organics Limited (MANGALAM) overvalued or undervalued?
What is the fair value of MANGALAM?
What is the quality score of MANGALAM?
What is the price target for Mangalam Drugs And Organics Limited (MANGALAM)?
What is the Mangalam Drugs And Organics Limited stock forecast for 2026?
What is the revenue of Mangalam Drugs And Organics Limited (MANGALAM)?
Does Mangalam Drugs And Organics Limited pay a dividend?
How much is the dividend of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the intrinsic value of Mangalam Drugs And Organics Limited (MANGALAM)?
Is Mangalam Drugs And Organics Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of MANGALAM?
How much is Mangalam Drugs And Organics Limited worth?
What do the bullish and bearish scenarios say about MANGALAM?
How solid is the balance sheet of Mangalam Drugs And Organics Limited (MANGALAM)?
How far is MANGALAM from its 52-week high?
Which stocks are comparable to Mangalam Drugs And Organics Limited?
Is Mangalam Drugs And Organics Limited stock attractive at the current price?
How is the fair value of MANGALAM calculated?
Is it still worth investing in stocks now?
What is the share price of Mangalam Drugs And Organics Limited (MANGALAM)?
What should I pay attention to with Mangalam Drugs And Organics Limited right now?
Key figures of Mangalam Drugs And Organics Limited
How large is the market capitalisation of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the P/S ratio of Mangalam Drugs And Organics Limited (MANGALAM)?
What are the earnings per share of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the dividend yield of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the net margin of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the return on equity of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the EBIT return on assets of Mangalam Drugs And Organics Limited (MANGALAM)?
What is the operating margin of Mangalam Drugs And Organics Limited (MANGALAM)?
How fast is revenue growing at Mangalam Drugs And Organics Limited (MANGALAM)?
How fast are earnings growing at Mangalam Drugs And Organics Limited (MANGALAM)?
How much free cash flow does Mangalam Drugs And Organics Limited (MANGALAM) generate?
How much net debt does Mangalam Drugs And Organics Limited (MANGALAM) carry?
Watch Mangalam Drugs And Organics Limited in the live analysis
One click puts Mangalam Drugs And Organics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.